Livtencity Tablet, Coated
NDC 64764-800
Product Information
Livtencity (maribavir) is a NDA-approved product labeled by Takeda Pharmaceuticals America, Inc.. This medication is typically used as a breast cancer resistance protein inhibitors [moa]. It is supplied as a blue tablet, coated for oral administration. This product entry covers the primary NDC 64764-800 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
SHP;620
Code Structure Chart
Product Details
What is NDC 64764-800?
What are the uses of this product?
What are Active Ingredients of this product?
- MARIBAVIR 200 mg/1 - has antiviral activity against human cytomegalovirus
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- MARIBAVIR (UNII: PTB4X93HE1)
- MARIBAVIR (UNII: PTB4X93HE1) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
- TALC (UNII: 7SEV7J4R1U)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2586073 - maribavir 200 MG Oral Tablet
- RxCUI: 2586079 - LIVTENCITY 200 MG Oral Tablet
- RxCUI: 2586079 - maribavir 200 MG Oral Tablet [Livtencity]
- RxCUI: 2586079 - Livtencity 200 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A4 Inhibitors - [MoA] (Mechanism of Action)
- Cytomegalovirus pUL97 Kinase Inhibitor - [EPC] (Established Pharmacologic Class)
- Cytomegalovirus pUL97 Kinase Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.